OR WAIT null SECS
March 23, 2023
Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.
March 22, 2023
The decision was based on results from the PROpel Phase III trial.
This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.
March 17, 2023
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
March 14, 2023
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
March 08, 2023
Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.
March 03, 2023
EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.
March 02, 2023
Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.
Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.